191 related articles for article (PubMed ID: 2976406)
21. Benefit of progressively increasing doses during the initial treatment with acitretin in psoriasis.
Berbis P; Geiger JM; Vaisse C; Rognin C; Privat Y
Dermatologica; 1989; 178(2):88-92. PubMed ID: 2522405
[TBL] [Abstract][Full Text] [Related]
22. [Etretinate: pro and con. Risk-benefit analysis of systemic retinoid therapy in psoriasis and recent developments: free aromatic acid, arotinoids].
Gollnick H; Orfanos CE
Hautarzt; 1985 Jan; 36(1):2-9. PubMed ID: 3156105
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study.
Dogra S; Jain A; Kanwar AJ
J Eur Acad Dermatol Venereol; 2013 Mar; 27(3):e305-11. PubMed ID: 22816881
[TBL] [Abstract][Full Text] [Related]
24. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study.
Murray HE; Anhalt AW; Lessard R; Schacter RK; Ross JB; Stewart WD; Geiger JM
J Am Acad Dermatol; 1991 Apr; 24(4):598-602. PubMed ID: 1827800
[TBL] [Abstract][Full Text] [Related]
25. International studies of the efficacy of etretinate in the treatment of psoriasis.
Ehmann CW; Voorhees JJ
J Am Acad Dermatol; 1982 Apr; 6(4 Pt 2 Suppl):692-6. PubMed ID: 7040512
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients.
Larsen FG; Jakobsen P; Larsen CG; Kragballe K; Nielsen-Kudsk F
Pharmacol Toxicol; 1988 Mar; 62(3):159-65. PubMed ID: 2967472
[TBL] [Abstract][Full Text] [Related]
27. Pilot study of a new retinoid, Ro 12-7554, in psoriasis and in some congenital disorders of keratinization.
Ott F; Bounameaux Y
Dermatologica; 1983; 167(1):52-3. PubMed ID: 6226548
[TBL] [Abstract][Full Text] [Related]
28. Treatment of severe psoriasis with etretin (RO 10-1670).
Lassus A; Geiger JM; Nyblom M; Virrankoski T; Kaartamaa M; Ingervo L
Br J Dermatol; 1987 Sep; 117(3):333-41. PubMed ID: 2890369
[TBL] [Abstract][Full Text] [Related]
29. [Pharmacokinetics of etretinate, acitretin and 13-cis-acitretin: new results and advantages of blood level oriented clinical use].
Gollnick H; Rinck G; Bitterling T; Orfanos CE
Z Hautkr; 1990 Jan; 65(1):40-50. PubMed ID: 2139274
[TBL] [Abstract][Full Text] [Related]
30. Serum levels of Etretinate (Ro 10-9359) and its metabolite (Ro 10-1670).
Ishizaki H; Masuda H; Kaseda H; Kaminaga T; Hirone T
J Dermatol; 1983 Oct; 10(5):421-6. PubMed ID: 6230381
[No Abstract] [Full Text] [Related]
31. Treatment of psoriasis with etretin: a preliminary report.
Madhok R; Muller SA; Dicken CH
Mayo Clin Proc; 1987 Dec; 62(12):1084-9. PubMed ID: 2960861
[TBL] [Abstract][Full Text] [Related]
32. Risk: benefit ratio in the treatment of psoriasis with systemic retinoids.
Halioua B; Saurat JH
Br J Dermatol; 1990 Jun; 122 Suppl 36():135-50. PubMed ID: 2142437
[TBL] [Abstract][Full Text] [Related]
33. Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359).
Lassus A
Br J Dermatol; 1980 Feb; 102(2):195-202. PubMed ID: 6992833
[TBL] [Abstract][Full Text] [Related]
34. Acitretin. A review of its pharmacology and therapeutic use.
Pilkington T; Brogden RN
Drugs; 1992 Apr; 43(4):597-627. PubMed ID: 1377120
[TBL] [Abstract][Full Text] [Related]
35. Plasma and suction blister fluid levels of etretinate and its main metabolite during treatment of psoriasis.
Lauharanta J; Paravicini U
Arch Dermatol Res; 1982; 272(1-2):147-9. PubMed ID: 6219628
[No Abstract] [Full Text] [Related]
36. Clinical trial of the efficacy and safety of oral etretinate with calcipotriol cream compared with etretinate alone in moderate-severe psoriasis.
Giannetti A; Coppini M; Bertazzoni MG; Califano A; Altieri E; Pazzaglia A; Lega M; Lombardo M; Pelfini C; Veller Fornasa C; Rabbiosi G; Cespa M
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):91-5. PubMed ID: 10568486
[TBL] [Abstract][Full Text] [Related]
37. Etretinate: effect of milk intake on absorption.
DiGiovanna JJ; Gross EG; McClean SW; Ruddel ME; Gantt G; Peck GL
J Invest Dermatol; 1984 Jun; 82(6):636-40. PubMed ID: 6233379
[TBL] [Abstract][Full Text] [Related]
38. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
39. Etretinate may work where acitretin fails.
Bleiker TO; Bourke JF; Graham-Brown RA; Hutchinson PE
Br J Dermatol; 1997 Mar; 136(3):368-70. PubMed ID: 9115918
[TBL] [Abstract][Full Text] [Related]
40. In vitro interactions of the aromatic retinoids Ro 10-9359 (etretinate) and Ro 10-1670 (acitretin), its main metabolite, with human serum lipoproteins and albumin.
Carillet V; Morlière P; Mazière JC; Hüppe G; Santus R; Dubertret L
Biochim Biophys Acta; 1990 Nov; 1055(2):98-101. PubMed ID: 2146977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
